p-AKT (Thr308), p-S6 ribosomal protein (Ser235/236) and caspase-3 by 2 to 4 hours with durable effects. PCNA was slightly reduced at an early time point. (TIF) Figure S6 Five chemotherapeutic agents induce dose and time dependent cytotoxicity in 4 anaplastic thyroid cancer cell lines. Dose-response curves were obtained on day 3 and 4 from cells treated with serial dilutions of chemotherapeutic agents (paclitaxel, irinotecan, etoposide, 5-FU, doxorubicin) for a 4-day course on ATC cell lines using LDH assays. All drugs demonstrated dose and time dependent cytotoxicity in four cell lines. (TIF) References 1. Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295: 2164–2167. 2. Chen AY, Jemal A, Ward EM (2009) Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 115: 3801–3807. 3. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, et al. (2009) Mutational profile of advanced primary and metastatic radioactive iodine- refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69: 4885–4893. 4. Nikiforov YE, Nikiforova MN (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7: 569–580. 5. Sippel RS, Kunnimalaiyaan M, Chen H (2008) Current management of medullary thyroid cancer. Oncologist 13: 539–547. 6. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550–562. 7. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671–688. 8. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/ AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988–1004. 9. Wu G, Mambo E, Guo Z, Hu S, Huang X, et al. (2005) Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90: 4688–4693. 10. Hou P, Liu D, Shan Y, Hu S, Studeman K, et al. (2007) Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cance. Clin Cancer Res 13: 1161–1170. 11. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI (2008) Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93: 278–284. 12. Liu Z, Hou P, Ji M, Guan H, Studeman K, et al. (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93: 3106–3116. 13. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, et al. (2008) Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 93: 611–618. 14. Wang Y, Hou P, Yu H, Wang W, Ji M, et al. (2007) High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab 92: 2387–2390. 15. Carlomagno F, Santoro M (2011) Thyroid cancer in 2010: a roadmap for targeted therapies. Nat Rev Endocrinol 7: 65–67. 16. Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, et al. (2011) Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. J Clin Endocrinol Metab 96: 2146–2153. 17. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphati- dylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851–1863. 18. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. (2008) NVP- BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022–8030. 19. Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, et al. (2009) Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 7: 601–613. 20. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, et al. (2010) NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16: 530–540. 21. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, et al. (2010) Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16: 5424– 5435. 22. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, et al. (2011) Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin Thyroid Cancer and NVP-BEZ235 Acknowledgments We acknowledge Novartis Pharmaceuticals Corporation (Basel, Switzer- land) for providing NVP-BEZ235. We thank the Laboratory Animal Center and Tissue Bank of Chang Gung Memorial Hospital at Linkou for technical support. Author Contributions Conceived and designed the experiments: SL YH RJW. Performed the experiments: SL CH. Analyzed the data: SL YH JL TC CH RJW. Contributed reagents/materials/analysis tools: SL YH TC. Wrote the paper: SL YH JL TC CH RJW. using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 17: 2373–2384. 23. Ohta K, Pang XP, Berg L, Hershman JM (1997) Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor. J Clin Endocrinol Metab 82: 2633–2638. 24. Huang YY, Yu Z, Lin SF, Li S, Fong Y, et al. (2007) Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab 92: 1965–1970. 25. Lin SF, Yu Z, Riedl C, Woo Y, Zhang Q, et al. (2007) Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery 142: 976–983; discussion 976–983. 26. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, et al. (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentifica- tion. J Clin Endocrinol Metab 93: 4331–4341. 27. Chou TC, Martin N (2005) CompuSyn for Drug Combinations: PC Software and User’s Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50 and ED50 and LD50 Values. Paramus: ComboSyn. 28. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55. 29. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621–681. 30. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440–446. 31. Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547–566. 32. Hughes AN, Griffin MJ, Newell DR, Calvert AH, Johnston A, et al. (2000) Clinical pharmacokinetic and in vitro combination studies of nolatrexeddihy- drochloride (AG337, Thymitaq) and paclitaxel. Br J Cancer 82: 1519–1527. 33. Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, et al. (2001) Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol 12: 1631–1641. 34. Sprinz E, Caldas AP, Mans DR, Cancela A, DiLeone L, et al. (2001) Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. Am J Clin Oncol 24: 177–184. 35. Foster KG, Fingar DC (2010) Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285: 14071–14077. 36. Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, et al. (2008) Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 21: 231–237. 37. Motti ML, Califano D, Troncone G, De Marco C, Migliaccio I, et al. (2005) Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol 166: 737–749. 38. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, et al. (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65: 10992–11000. 39. Kim SH, Juhnn YS, Song YS (2007) Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci 1095: 82–89. 40. Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL (2010) Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer 126: 1144–1154. 41. Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10: 587–594. 42. Fekete M, Santiskulvong C, Eng C, Dorigo O (2012) Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells. Anticancer Res 32: 445–452. PLOS ONE | www.plosone.org 11 October 2012 | Volume 7 | Issue 10 | e46726